Fin Posillipo
Also known as Fin Posillipo S.p.A., FinPosillipo
Holding founded in 1989 and controlled by the Petrone family; majority shareholder of Pierrel and an investor in BetaGlue Therapeutics.
USEFUL FOR Co-investors
Holding of the Petrone family (Petrone Group, Pierrel). Not other companies using the Posillipo name.
Family & background
- FAMILY
- Petrone
- HEADQUARTERS
- Italy
- FOUNDED
- 1989
Investment approach
- SECTORS
- Biotech & Life Sciences
- ROUTES
- Companies (own capital)
Overview
Fin Posillipo S.p.A. is a holding company founded in 1989 and controlled by the Petrone family, according to the Petrone Group website, which describes it as managing a diversified portfolio of investments. It held about 79.27% of Pierrel; in November 2023 PRL S.p.A., acting in concert with Fin Posillipo, launched a voluntary tender offer for the rest of Pierrel aimed at delisting, and holdings of the parties acting in concert passed 90% on 28 November 2023. In June 2024 it took part in BetaGlue Therapeutics' €8M equity round.
Holdings & investments (2)
- PierrelNOTABLEBiotech & Life Sciences · Majority stake (about 79.27% before the 2023 delisting offer)
- Biotech & Life Sciences
Frequently asked questions
Fin Posillipo is a family holding based in Italy, founded in 1989.
Fin Posillipo invests on behalf of the Petrone family.
Fin Posillipo invests its own capital into companies.
Fin Posillipo invests in Biotech & Life Sciences.
Fin Posillipo's holdings and investments include Pierrel and BetaGlue Therapeutics.
The most recent publicly reported investment by Fin Posillipo is BetaGlue Therapeutics (€8M equity round led by Neva SGR and LIFTT, with participation of FinPosillipo (Petrone Group)), announced in Jun 2024.